GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

The Bombay High Court emphasized that the statutory requirement for a pre-deposit could not be circumvented through a writ petition. The Court pointed out that the issue raised was not purely a legal ...

Explore the detailed Glaxo Smith Kline balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...

The new facility at Stainton, near Barnard Castle, will power the nearby Glaxo Smith Kline factory for 40 years ...

The South African Communist Party (SACP) in the Western Cape has learnt that several employees who work for Glaxo Smith Kline (GSK) pharmaceutical company based in Epping, Cape Town, have tested ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...